Background: The brain-derived neurotrophic factor (BDNF) gene is involved in mechanisms of synaptic plasticity in the brain and has been demonstrated to also play a role in influencing brain plasticity induced by transcranial magnetic and electrical stimulation.
introduction
Val66Met (rs6265) is a single nucleotide polymorphism (SNP) in the brain-derived neurotrophic factor (BDNF) gene that codes for the protein BDNF. [1] Many studies have confirmed the role of BDNF in regulating synaptic consolidation in adults and neural plasticity. [2] [3] [4] [5] [6] When the substitution of Met for Val occurs at position 66 in the pro-region of the BDNF gene, altered activity-dependent release and recruitment of BDNF in neurons can be observed. [7] This is believed to manifest in an altered ability to induce neuroplasticity in the human brain. Many studies using non-invasive neuroplasticity-inducing protocols have investigated the impact of the BDNF polymorphism on cortical modulation and plasticity, usually by investigating the excitability alterations in the primary motor cortex (M1) induced by different transcranial stimulation methods. [8] [9] [10] [11] [12] [13] However, the results are partly contradictory and mainly dependent on the paradigm used in a given study. Originally [8] for intermittent theta burst stimulation (iTBS), continuous theta burst stimulation (cTBS), paired associative stimulation (PAS) and combined transcranial direct current stimulation/ repetitive transcranial magnetic stimulation (tDCS/rTMS) metaplasticity (e.g. 1Hz rTMS) protocols, Met carriers showed a reduced response to iTBS cTBS and to PAS protocols compared to Val66Val individuals. This was essentially confirmed later in a retrospective study [9] reporting that Val66Val individuals showed larger MEP responses than Val66Met subjects after iTBS. In contrast, other studies observed that the aftereffects of iTBS [10] or quadripulse stimulation (QPS) [12] could not be modulated by the BDNF Val66Met polymorphism. Similarly, no difference in homeostatic metaplasticity between Val66Val participants and Met carriers in a three-session, repeated measures (cTBS followed by cTBS, cTBS followed by iTBS, and iTBS followed by iTBS) paradigm [11] was seen. For tDCS, the aftereffects of 7-10min anodal and cathodal stimulation on MEP amplitudes was shown to be greater for Met carriers, but this finding was not statistically significant. [9] This was confirmed by another study using a 20 min stimulation duration [14] and also in the case of transcranial random noise stimulation (tRNS). [9] The results summarized above suggest that Met carriers might be less likely to undergo neuroplastic changes using some of the stimulation protocols. It is possible that the Met carriers are the 'non-responders', who are commonly attributed to their unability to relax during measurements in each laboratory using transcranial stimulation methods. The question rises, whether we should always consider this genetical factor, when we are using transcranial stimulation in a laboratory environment. Here we have updated our previous observations [9] in a larger subject population including 115 healthy subjects and 130 measurements and again, using a retrospective approach with participants grouped according to genotype. Besides the increase in the number of subjects we included data using transcranial alternating current stimulation (tACS). The results still suggest some trends toward specific plasticity induction protocols being dependent on BDNF polymorphisms, however, without statistical significance.
MAteriAl And Methods

Subjects
Altogether the data of 115 healthy volunteers (age range: 19-40 years) participating in 130 experimental sessions was analysed (Table. 01 ). Subjects were included in this retrospective analysis study after giving written informed consent. None of them suffered from any neurological or psychological disorders, none had metallic implants or implanted electric devices or took any medication prior to the experimental sessions or on a regular basis. We conform to the Declaration of Helsinki and the retrospective analysis was approved by the Ethics Committee of the University of Göttingen.
Experimental procedure
Healthy subjects who had participated in our previous experiments using transcranial stimulation methods were asked to participate in the BDNF genotyping study. [9, [15] [16] [17] [18] [19] [20] [21] Unfortunately not all the subjects could be contacted, and a few refused to participate in the genotyping study. In addition, not all of the subjects participated in all of the stimulation conditions. Therefore the number of subjects in the different experimental sessions varies (Table. 01). After successful genotyping, the previously recorded MEP data from Val66Val homozygotes and Val66Met heterozygotes were identified and analysed.
Stimulation
Genotype Subjects 
BDNF genotyping
Whole blood was vacuum extracted into EDTA tubes and DNA was sampled using standard laboratory procedures. Primer sequences and PCR conditions are available upon request from M. Shoukier). PCR analysis was checked for positive sequence markers on agarose/2 x TBE gels. Restriction Fragment Length Polymorphism (RFLP) analysis was performed by digesting the PCR product with the restriction enzyme Hsp92II. RFLP-conditions are available upon request. Restriction products were then electrophoresed on a 2% agarose gel and visualized using a transilluminator and ethidium bromide staining. After digestion the Val allele (G) gave two fragments: 57 and 217 bp, whereas the Met allele (A) gave three: 57, 77 and 140 bp. The 115 participants were genotyped as follows: 69 participants were found to be homozygous for the Val allele (Val66Val), 40 were Val66Met heterozygotes and 6 were homozygous for the Met allele. The Met homozygotes were not included in this analysis. The blood sampling was done on non-experimental days, and the period between the last experimental session and the taking of the blood sample was between 1 day and 2 months.
MEP measurement
The MEP registration protocols are described in detail in previous publications. [9, [15] [16] [17] [18] [19] [20] [21] Briefly, subjects were seated in a comfortable reclining chair with a mounted headrest throughout the experiments. Within each type of experimental session the measurements were always performed by the same experienced investigator. To detect current-driven changes in cortical excitability, MEPs of the right ADM or FDI were recorded following stimulation of its motor-cortical representation using single-pulse TMS. These were elicited using a Magstim 200 or using MagPro magnetic stimulator, with a figure-of-eight standard magnetic coil (diameter of one winding, 70 mm). Surface electromyography (EMG) was recorded from the right FDI and ADM muscle through a pair of Ag-AgCl electrodes in a belly-tendon montage. Raw signals were amplified, band-pass filtered (2Hz-3kHz; sampling rate 5 kHz), digitized with a micro 1401 AD converter (Cambridge Electronic Design, Cambridge, UK) controlled by Signal Software (version 2.13). Complete relaxation was controlled through visual feedback of EMG activity. The coil was held tangentially to the skull, with the handle pointing backwards and laterally at 45° from the midline, resulting in a posterior-anterior current flow direction in the brain. The optimum position was defined as the site where TMS resulted consistently in the largest and most stable MEP in the resting muscle. The intensity required to evoke a MEP of ~ 1mV peak-to-peak amplitude (SI1mV) and a baseline of 
Electrical and magnetic stimulation: tRNS, tDCS, tACS and iTBS
Electrical stimulation was delivered using a battery-driven electrical stimulator (DC-Stimulator-Plus, NeuroConn GmbH, Ilmenau, Germany) through conductive-rubber electrodes, placed in two saline-soaked sponges. The stimulation electrode was placed over the left M1, which was determined by single-pulse TMS. The reference electrode was placed over the contralateral orbit. The stimulation intensity was 1 mA. The detailed description of the stimulation conditions can be found in previous publications. [9, [15] [16] [17] [18] [19] [20] [21] In summary: tRNS -(n=43; 13 heterozygotes): In the stimulation mode "noise" there is a random output of current generated for every sample. [15] The random numbers are normally distributed; the probability density function follows a bell-shaped curve. In the frequency spectrum all coefficients have a similar size. The noise signal contains all frequencies up to half of the sampling rate, i.e. a maximum of 640 Hz. The size of the stimulation electrode was 4x4 cm and the reference electrode was 6x14 cm. TRNS was applied for 10 minutes.
tDCS -(n=32; 32 anodal stimulation; 13 heterozygotes and 19 cathodal stimulation, 8 heterozygotes): Here the electrode size was 5x7 cm. Stimulation was performed for 7 (2 subjects) 10 (25 subjects) or 13 (5 subjects) and 9 (2 subjects) or 10 (17 subjects) minutes (for anodal and cathodal stimulation polarities respectively, according to the different protocols from each study).
tACS -(n=13; 6 heterozygotes): tACS was applied for 10 min with a current intensity of 1 mA and with a frequency of 140 Hz. The waveform of the stimulation was sinusoidal without a DC offset. The current was ramped up and down over the first and last 5 s of stimulation. Here the electrode size over the M1 was 4x4 cm whereas the reference electrode size at the forehead was 14 x 6 cm. was 80% of active motor threshold (AMT). AMT was defined as the lowest stimulus intensity at which three of six consecutive stimuli elicited reliable MEPs (~200 μV in amplitude) in the tonically contracting the right first dorsal interosseous (FDI) or the abductor digiti minimi (ADM) muscle. The pattern of iTBS consisted of bursts of stimuli containing 3 pulses at 50 Hz repeated at 200 ms intervals (i.e., at 5 Hz). A 2s train of TBS was repeated every 10s for a total of 190 s (600 pulses).
Data analyses
In order to estimate the numbers of subjects needed in each group power analysis were done based on the results of previously published data [8, 9] (with regard to tRNS and tACS there are no data available). In order to detect the difference in the mean MEP size between Val/Val and Val/Met subjects with 95% confidence and 80% power, in the iTBS group min. 8, in the tDCS group 11 Val66Met subjects should be included.
Student's t-test was used to compare baseline with post-stimulation MEP amplitudes within one condition and considering only one genotype, in order to see if the given stimulation condition had an effect. After it repeated measures ANOVAs with the between subject factor GENOTYPE, the within subject factor TIME (before, 0-5, 10-15, 25-30, 55-60 min post-stimulation) and the dependent variable MEP amplitude were used to compare the effects of neuroplasticity-induction and different stimulation methods among individuals. Effects were considered significant if p<0.05. The results were not Bonferroni corrected for multiple testing. All data are given as means + SEM. 
Figure. 01 Effect of BDNF polymorphism on iTBS
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Figure. 01 Effect of BDNF Val66Met polymorphism on cortical excitability in response to iTBS. There was a significant increase in MEPs after iTBS in the Val66Val group, but not in the Val66Met group. Data are mean (+ S.E.M.) peak-to-peak amplitudes of MEP.
The ANOVA revealed no significant main effect of GENOTYPE (F 1,12 =0.57; p=0.45) and GENOTYPE x TIME interaction (F 4,84 =0.61; p=0.65). The effect of TIME was significant (F 4,84 =4.71; p=0.002).
tDCS:
With regard to anodal stimulation there was a significant increase in MEP size after anodal tDCS in both groups compared to the baseline MEPs but the excitability enhancement was more pronounced in the Val66Met group (Val66Val group: during the first 30 min 2.57<t>3.91, p<0.02; Val66Met group: up to 60 min 3.12<t>5.61, p<0.01) (Figure. 02 ).
The ANOVA revealed no significant main effect of GENOTYPE (F 1,30 =2.99; p=0.09), and GENOTYPE x TIME interaction (F 4,120 =2.12; p=0.08). The effect of TIME (F 4,120 =6.42; p=0.0001), however, was significant. The ANOVA revealed no significant main effect of GENOTYPE (F 1,17 =0.93; p=0.34), however the effect of TIME was significant (F 4,68 =9.57; p=0.0001). The GENOTYPE x TIME interaction was not significant (F 4,68 =1.45; p=0.22).
tRNS:
The t-test showed that there was a significant increase in MEP amplitude after tRNS in both groups at all timepoints compared to the baseline (Val66Val group: 3.86<t>5.3, p<0.004; Val66Met group: 2.50<t>4.1, p<0.03) (Figure. 03 ).
The ANOVA revealed no significant main effect of GENOTYPE (F 1,41 =0.88; p=0.35), and GENOTYPE x TIME interaction (F 4,164 =0.74; p=0.56). The effect of TIME was significant (F 4,164 =8.14; p=0.0005).
tACS:
According to the t-test there was a significant increase in MEP size after tACS in both groups but the excitability enhancement was more pronounced in the Val66Val group (Val66Val group: at 10 and 30 min: 3.4<t>3.86, p<0.02; Val66Met group: only at 10 min t=3.27, p=0.02) (Figure. 04 ).
The ANOVA revealed no significant main effect of GENOTYPE (F 1,11 =0.76; p=0.4), TIME (F 4,44 =2.13; p=0.09) and GENOTYPE x TIME interaction (F 4,44 =0.91; p=0.46).
We observed that although we had a higher number of Val66Met subject in the iTBS and tDCS groups than according the sample size calculation should be, the GENOTYPE x TIME interactions remained non-significant. According to the power analysis based on the mean differences of the present data (alpha set at 0.05) a sample size (Val66Met) of 18 a-tDCS, 17 c-tDCS, 12 tACS, 15 iTBS would be necessary.
Comparing the excitability enhancing protocols
The ANOVA revealed no significant main effect of GENOTYPE (F 1,103 =0.82; p=0.34), and there were no significant GENOTYPE x STIMULATION (F 3,103 =1.12; p=0.35) and GENOTYPE x STIMULATION x TIME interactions (F 12,412 =0.80; p=0.65). There was a significant main effect of STIMULATION (F 3,103 =5.65; p=0.001) and the STIMULATION x TIME interaction was also significant (F 12,412 =1.8; p=0.05) (Figure. 05) . 
discussion
In this study we were unable to observe statistically significant effects demonstrating the impact of the BDNF polymorphism on neuroplasticity-inducing methods after comparing a variety of different transcranial stimulation protocols, although some trends were seen. These negative results might be related to the low numbers of subjects in the Val66Met group, although the sample size calculations based on previous results suggested that at least in the iTBS and tDCS groups the number of subjects should be sufficient. According to these data, we have to consider that the association between genotype and the effect of transcranial neuromodulation less important and might be an artifact of small sample sizes. On the whole, the finding of a rather weak BDNF effect is in accordance with previous literature reporting contradictory findings. [10] [11] [12] 22] Therefore, we suggest that the effort given to genotyping subjects for the purpose of examining plasticity-induction in transcranial magnetic or electrical stimulation studies has probably not been rewarded sufficiently by clearer results.
There is no doubt that BDNF plays a very important role in the effects that transcranial stimulation techniques have on the brain. [23] [24] [25] Fritsch et al. [23] have measured BDNF levels before and after anodal DCS in rat brain slices and found that combined DCS and low frequency stimulation enhanced BDNF-secretion and tyrosine kinase receptor activation. In another study reduced BDNF expression was found in cathodally stimulated rat brain slices. [24] An interesting question concerns the interaction between BDNF and stimulation duration. It was reported that a longer stimulation duration of 30 min. (such as those used in quadri-pulse stimulation (QPS) paradigms), [12] may be able to overrun BDNF sensitivity, compared to a short TBS protocol lasting between 40 s and 3 min. This is essentially compatible with a negative finding for a 20 min tDCS stimulation protocol. [14] tRNS aftereffects appear to be the least affected by BDNF variants (Figure. 03) , which is in line with a different physiological mechanism of action. Interestingly, 140 Hz tACS showed a similar effect to iTBS. We observed that in Val66Val individuals, tACS facilitated MEPs stronger, than in subjects carrying the Met allele, however, this effect was not significant. The working mechanism for this tACS frequency has not yet been ascertained, nevertheless the involvement of GABAA receptors have been implicated. [16] On the cellular level, BDNF secretion is altered by the application of electrical currents, and it has been shown that combined direct current stimulation and low frequency stimulation enhances BDNF-secretion and TrkB activation. [18] While mechanisms of neuroplasticity induction involve the potentiation of NMDA receptors [26] amongst other neurotransmitters, it may be plausible that either transcranial stimulation methods alter BDNF secretion, or that altered levels of BDNF under targetted areas can impact upon the inducible aftereffects of these stimulation methods.
One of the limitations of our study is that it is a retrospective analysis and therefore the number, the age and the male/female distribution of the homo-and heterozygote groups could not exactly be matched. Although our subjects were within the same age-range, the ratio of females/males was slightly different between the two populations. Our Gender x Genotype analysis did not result in significant interaction (p=0.6). The socioeconomic background of the subjects was not explored and the educational level of the subject was close to the same, 90% of the subjects were university students. Therefore, the current results have to be replicated and validated in a dedicated prospective study. Furthermore, the results described here may not be widely applicable with regard to the stimulation of other areas or using other type of tasks. Previous findings from different groups [27] [28] [29] [30] have found bilateral reduction of hippocampal gray matter volumes in Met BDNF-carriers compared with Val66Val subjects, although later investigations have failed to reproduce this finding. [31, 32] It has also described that Met carriers have smaller parahippocampal areas and a smaller thalamus compared to Val/ Val subjects. Additional loci of reduced gray matter volumes were found in the frontal areas, including the lateral convexity of the frontal lobes with peak values encompassing the dorsolateral prefrontal cortex bilaterally. [27, 28] Accordingly, cognitive studies investigating hippocampus-dependent declarative memory functions (especially concerning paradigms measuring episodic memory) have shown altered memory recall, reporting an association between a decrease in episodic memory function in Met carriers, when compared to Val homozygotes. [27, [33] [34] [35] Furthermore, it is also not yet known, whether results derived from studies conducted on healthy populations can be directly translated to patient populations. A study investigated the role of the BDNF polymorphism in response to rTMS in patients affected by mood disorders. [36] rTMS treatment improved depression symptomatology and the response was significantly greater in Val homozygotes than in Met allele carriers. Nevertheless, in another study no effect of BDNF polymorphism was observed when depressive patients with anodal tDCS were treated. [37] Yet these results have limited generalizability, because we have no information concerning other diseases.
Recently, the interaction between BDNF Val/Met and COMT Val/Met genotypes on paired associative stimulation (PAS)-induced plasticity was described.
[38] In BDNF/Val homozygotes PAS-induced plasticity was stronger if participants were also COMT/Met homozygotes, compared with BDNF/Met carriers. Therefore, it is very likely that additional genes and polymorphisms can also influence the effect of transcranial stimulation methods.
